Sun Pharmaceutical Industries Limited announced the establishment of the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai. The initiative is supported by a $2.5 million endowment from Sun Pharma to fund academic leadership in perpetuity.

Mark G. Lebwohl, M.D., has been installed as the inaugural professor. The ceremony took place on October 6, 2026, at Hatch Auditorium at The Mount Sinai Hospital in New York. The professorship is based within the Kimberly and Eric J. Waldman Department of Dermatology.

Strategic Alignment with Core Business

Sun Pharma identifies itself as the second-largest pharmaceutical dermatology company in the U.S. by prescription volume. This endowment aligns with its broader commitment to advancing patient care through scientific innovation and education. The company’s Global Innovative Medicines portfolio, which includes dermatology products, accounts for about 22% of total sales.

Leadership and Institutional Impact

Dr. Lebwohl serves as Dean for Clinical Therapeutics at the Icahn School of Medicine and Professor and Chairman Emeritus of the Department of Dermatology. He is internationally recognized for his contributions to psoriasis research and for shaping standards of care in inflammatory skin diseases.

Ahmad Naim, M.D., Senior Vice President and Chief Medical Officer, North America, stated that the professorship reflects a long-term commitment to fostering academic leadership needed to pursue new ideas and strengthen care for generations to come.

Emma Guttman, M.D., Ph.D., Waldman Professor and System Chair of the Department of Dermatology, noted that the partnership reflects a shared belief in investing in scientific excellence. Eric J. Nestler, M.D., Ph.D., Dean of the Icahn School of Medicine, described the professorship as a fitting recognition of Dr. Lebwohl's impact on the field.

What the Numbers Show

The $2.5 million endowment is structured to support research, education, and mentorship indefinitely. By anchoring this funding within a department where it already holds significant market presence, Sun Pharma reinforces its position in the U.S. dermatology sector. The move highlights a strategic focus on long-term academic influence rather than short-term commercial returns.

Sun Pharmaceutical Industries Limited has initiated a postal ballot to secure shareholder approval for its new Employee Stock Option Plan 2026 (ESOP 2026) and significant enhancements to its borrowing and investment limits. These approvals are critical to facilitating the proposed acquisition of Organon & Co., a strategic move aimed at diversifying the company's global pharmaceutical portfolio.

ESOP 2026 framework and dilution impact

The company proposes adopting the ESOP 2026, which will be implemented through an irrevocable employee welfare trust. This plan allows for the grant of up to 12,000,000 options, each conferring the right to acquire one existing fully paid-up equity share. Crucially, the plan utilizes shares acquired from the secondary market, ensuring no fresh equity issuance and thus preventing dilution of existing shareholders' holdings. The exercise price is set at ₹1 per option, aligning with the face value, and vesting is performance-linked, typically over a five-year period with three equal annual instalments.

Financing limits for Organon acquisition

To support the proposed acquisition of Organon, Sun Pharma seeks to enhance its financial authorities under the Companies Act, 2013. The current borrowing limit stands at ₹500 billion, approved in 2014. The proposal seeks to increase this cap to ₹700 billion. Additionally, the limit for loans, guarantees, securities, and investments under Section 186 is proposed to rise from ₹500 billion to ₹800 billion. These enhanced limits are intended to provide the necessary headroom for acquisition financing, refinancing, and integration costs.

Security creation and regulatory compliance

The ballot also includes a request to create security interests, including mortgages and charges, up to ₹700 billion in favor of lenders. A specific resolution seeks approval under Regulation 24(5) of the SEBI Listing Regulations to pledge shares of Organon and its subsidiaries. This encumbrance is required to secure financing facilities aggregating up to $12 billion. The company notes that while Organon may become a material subsidiary, this approval is sought as a matter of governance best practice to facilitate the financing structure without requiring separate approvals during potential enforcement events.

What the Numbers Show

The data reveals a substantial expansion in Sun Pharma's financial capacity relative to its current utilization. As of June 30, 2026, the company had utilized only ₹134.3 billion of its existing ₹500 billion borrowing limit, representing approximately 27% usage. The proposed increase to ₹700 billion provides a significant buffer, suggesting the acquisition financing requires substantial debt capacity beyond current headroom. Furthermore, the decision to implement ESOPs via secondary market purchases rather than fresh issues indicates a strategic preference for protecting existing shareholder value while still offering competitive long-term incentives tied to performance metrics like Net Sales and Earnings Before Tax.